Tigecycline: a new glycylcycline for treatment of serious infections. - Wikidata - awgldk - TriplyDB

Tigecycline: a new glycylcycline for treatment of serious infections.

Tigecycline: a new glycylcycline for treatment of serious infections.

http://www.wikidata.org/entity/Q36218312

about

"Stormy waters ahead": global emergence of carbapenemases Tigecycline in treatment of multidrug-resistant Gram-negative bacillus urinary tract infections: a systematic review Management of multidrug-resistant enterococcal infections Evaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill Experiments Antibiotics for emerging pathogens Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America Fatal cross infection by carbapenem-resistant Klebsiella in two liver transplant recipients IS5 element integration, a novel mechanism for rapid in vivo emergence of tigecycline nonsusceptibility in Klebsiella pneumoniae.Drug treatment for multidrug-resistant Acinetobacter baumannii infections.Tigecycline: a novel broad-spectrum antimicrobial.Genomic analysis of reduced susceptibility to tigecycline in Enterococcus faecium.Modulation of Bacterial Multidrug Resistance Efflux Pumps of the Major Facilitator Superfamily.Clostridium difficile: improving the prevention paradigm in healthcare settings.Excess deaths associated with tigecycline after approval based on noninferiority trials.Step-Wise Increase in Tigecycline Resistance in Klebsiella pneumoniae Associated with Mutations in ramR, lon and rpsJ Epidemiology and treatment of community-associated methicillin-resistant Staphylococcus aureus in children.Treatment options for multidrug-resistant bacteria.The In Vitro Evaluation of Tigecycline and the In Vivo Evaluation of RPX-978 (0.5% Tigecycline) as an Ocular Antibiotic.Investigational treatments for postoperative surgical site infections.KPC enzymes in the UK: an analysis of the first 160 cases outside the North-West region.Combating the growing problem of methicillin-resistant Staphylococcus aureus: do the newer antibiotics represent a better alternative to vancomycin?Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer.Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.Pharmacologic options for CNS infections caused by resistant Gram-positive organisms.In Vitro Activity of Tigecycline Against Orientia tsutsugamushi.Comparison of tigecycline and vancomycin for treatment of experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus Establishing the role of tigecycline in an era of antimicrobial resistance.Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients.Tigecycline for the treatment of patients with community-acquired pneumonia requiring hospitalization.Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux Resistant pathogen-associated skin and skin-structure infections: antibiotic options.Status report on carbapenemases: challenges and prospects.Efficacy and safety of tigecycline: a systematic review and meta-analysis.Pharmacokinetic and pharmacodynamic evaluation of tigecycline.Tigecycline-related pancreatitis: a review of spontaneous adverse event reports.Current treatment for nocardia infections.Antibiotic resistance in Enterococcus faecium clinical isolates.Vancomycin-resistant enterococcal bacteremia pharmacotherapy.Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials.

P2860

Q21131125-EFF8068B-7192-4A58-9C0D-7C3A12DF175E Q26823357-AECCD2C8-7C62-4D25-A131-BEF13FD2729C Q28285907-D6073248-89CF-4511-92DD-706B2B0F19D3 Q28550910-E7DE62C7-7835-4DC9-ACEB-03F4A9A2D189 Q29615377-6ACB99D9-0F9C-47A6-82E3-BBBE0F9A1486 Q29616084-C3FE8F7F-85A8-43B1-B5CC-ED021840F278 Q30433281-286C7747-0A0C-456C-8CED-86378C67BEAA Q34299132-8E69FC72-B0CF-4A8A-94FF-4FBB6B5F8482 Q34601684-DFE49CC1-F21E-4CB3-A586-A9B2B02596B5 Q34630833-2514C5AE-AB33-423A-9B90-A53D4BD2EEF5 Q34922281-94182BDC-8335-4A1D-A451-BA77B5874F49 Q35142025-C7C57414-BF3D-4F8B-AF1C-9F1E2CECED06 Q35222472-59D855B1-3E65-40EA-82D4-6F96301725B0 Q36115632-A2FB1AEB-FEBD-4176-88C4-54A8AB6D138F Q36169422-DC99B38F-6A61-42FA-830C-106A82F25C37 Q36379346-C852B8C4-FCAA-4706-B53F-4DA3A06A6CDB Q36607401-29684CA7-CEE2-4972-B18D-45DD16269387 Q36656768-0BD96D57-2DBA-4FA6-88EA-8A6A521EA8A7 Q36715742-0500BBD4-11DA-4E89-B06D-B0D40DBF5596 Q36794776-605A6107-8DC4-4D75-9A2C-19679F5CA73C Q36839693-DC990EF6-476B-482D-ABBF-4011B9AD4D5A Q37055211-3F5B72B2-7C86-4FDF-BF22-38D4F9C80327 Q37071199-6179C690-BB0C-4507-8509-BD800F6770ED Q37077629-43311115-E860-4EAF-A6FD-2B2FF72E0F74 Q37110121-ACD7D2E7-6BDB-4B6A-A3C6-BD36E8F5EAF5 Q37247619-F32AD875-B599-4CD7-88AF-201604048DAE Q37291328-AC748A47-6411-48E5-9CE4-5AFECB06F63D Q37377897-60416796-64B1-4E36-8409-0025B4628DA6 Q37532488-DF3F130C-500F-4D7F-8ED5-E3C4FDD53FA6 Q37608268-52F04EBA-89AB-4CBC-9297-34B5742EAFCB Q37679508-12935760-8929-46EF-AACA-710B18A53A63 Q37785546-CA21D6BC-83D4-4DB9-8072-9ABE94F6D807 Q37879199-3CE55705-468E-48C3-A0A0-81CDFF8F2B9C Q37891606-89994433-FF15-4BC7-92F7-8572AB9D3BD5 Q37940546-3F379035-615B-42A1-AD6B-F8C882AC0124 Q38073205-12AD4C25-1AC3-41FE-BF8E-2CE414BF9164 Q38149157-A02AB3B4-FB13-4FD9-8122-86AB1C445203 Q38176042-D8A21632-1CD2-4087-9392-E53B5996AFFB Q38263421-69B21A10-8A91-41E7-8FBF-8F74F27E98EF Q38286351-4B575524-259C-4B03-8125-7844EE5FC434

P2860

Tigecycline: a new glycylcycline for treatment of serious infections.

http://www.wikidata.org/entity/Q36218312

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Tigecycline: a new glycylcycline for treatment of serious infections.

@ast

Tigecycline: a new glycylcycline for treatment of serious infections.

@en

type

label

Tigecycline: a new glycylcycline for treatment of serious infections.

@ast

Tigecycline: a new glycylcycline for treatment of serious infections.

@en

prefLabel

Tigecycline: a new glycylcycline for treatment of serious infections.

@ast

Tigecycline: a new glycylcycline for treatment of serious infections.

@en

P1433

Q36218312-02A09EBE-8C76-44F6-B4C3-C80D69F5ECB4

P1476

Q36218312-B44A5FB3-43B9-4C17-BD0F-1EF45885D80B

P2093

Q36218312-FDC4D21F-1D42-4C50-99E2-70CF744654EE

P2860

Q36218312-135FDE67-3A23-4A22-8A73-B45FEB9F8470

Q36218312-16A644C7-2812-48E8-BCBF-C57766F6ADC2

Q36218312-172E0519-9E51-4AC1-99DD-AE8B71E5AC5C

Q36218312-260C0539-5061-4779-8915-4AED167E9AD6

Q36218312-26CBABD4-1C56-4B28-AB41-CBAE1FFEBA46

Q36218312-322FEA72-4394-4706-BF2C-FFE8D23C9A43

Q36218312-348ACD13-D9F1-4D18-BFE0-DBFE1DE4C7AD

Q36218312-34901260-422E-47B5-AFCA-3D54C8CCC576

Q36218312-47A1F4BA-BB04-4224-ACD9-EA25605DFDEB

Q36218312-4BB9516D-74AB-4CDA-A29A-06CEF8E68444

P304

Q36218312-1B647FB8-5E56-4465-88DC-A2D4A503B3E4

P31

Q36218312-281F2422-4CF8-4A9D-BFC5-7FDCDB10A7C6

P356

Q36218312-BC433920-70EA-4707-8772-083DF3B005F5

P407

Q36218312-E9E7381F-8968-4321-9B24-A8710B9564F2

P478

Q36218312-C3FF081E-45F1-4303-97CD-22D90F35AD47

P577

Q36218312-60C3CF35-EB11-4A11-9DE4-3F22BD440964

P5875

Q36218312-F5DE7FBF-F165-4A82-B778-D71061F98AFF

P698

Q36218312-75BD252D-EB20-4609-9B0C-D33177FBFE27

P356

P1433

Clinical Infectious Diseases

P1476

Tigecycline: a new glycylcycline for treatment of serious infections.

@en

P2093

Gary A Noskin

http://www.w3.org/2001/XMLSchema#string

P2860

Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia

The glycylcyclines: a comparative review with the tetracyclines

Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates

Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects

Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis.

In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria.

Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci.

In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.

In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain

Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center.

P304

S303-14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/431672

http://www.w3.org/2001/XMLSchema#string

P407

P478

41 Suppl 5

http://www.w3.org/2001/XMLSchema#string

P577

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7680066

http://www.w3.org/2001/XMLSchema#string

P698

16080069

http://www.w3.org/2001/XMLSchema#string